| [1] |
YU X J, LIANG M F, ZHANG S Y, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China[J]. N Engl J Med, 2011, 364(16): 1523-1532.
|
| [2] |
郑昕. 发热伴血小板减少综合征的再认识[J]. 中华传染病杂志,2024, 42(4): 193-197.
|
|
ZHENG X, Fever with thrombocytopenia syndrome recognized[J]. Chinese Journal of Infectious Diseases, 2024, 42(4): 193-197.
|
| [3] |
LUO N, LI M D, XU M, et al. Research progress of fever with thrombocytopenia syndrome[J]. Intensive Care Res, 2023: 1-10.
|
| [4] |
WU Y J, SUN X, KANG K, et al. Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms[J]. J Hematol Oncol, 2024, 17(1): 106.
|
| [5] |
中国医师协会血液科医师分会, 中华医学会儿科学分会血液学组, 噬血细胞综合征中国专家联盟, 等. 中国噬血细胞综合征诊断与治疗指南(2022年版)[J]. 中华医学杂志, 2022, 102(20): 1492-1499.
|
|
Hematology Branch of Chinese Medical Doctor Association, Hematology Group, Pediatric Branch, Chinese Medical Association, Chinese Expert Alliance on Hemophagocytic Syndrome, et al. Guidelines for the diagnosis and treatment of hemophagocytic syndrome in China (2022 edition)[J]. Chinese Medical Journal, 2022, 102(20):1492-1499.
|
| [6] |
黄晓霞, 杜珊珊, 李阿茜, 等. 2018—2021年中国发热伴血小板减少综合征流行特征分析[J]. 中华流行病学杂志, 2024, 45(1): 112-116.
|
|
HUANG X X, DU S S, LI A Q, et al. Epidemiological characteristics of fever with thrombocytopenia syndrome in China, 2018‒2021[J]. Chinese Journal of Epidemiology, 2024, 45(1):112-116.
|
| [7] |
中华医学会感染病学分会. 发热伴血小板减少综合征诊疗共识[J]. 中华传染病杂志, 2022, 40(12): 711-721.
|
|
Chinese Society of Infectious Diseases. Consensus on the diagnosis and treatment of fever with thrombocytopenia syndrome[J]. Chinese Journal of Infectious Diseases, 2022, 40(12): 711-721.
|
| [8] |
陈广, 陈韬, 舒赛男, 等. 重症发热伴血小板减少综合征诊治专家共识[J]. 中华临床感染病杂志, 2022, 15(4): 253-263.
|
|
CHEN G, CHEN T, SHU S N, et al. Expert consensus on the diagnosis and treatment of severe fever with thrombocytopenia syndrome[J]. Chinese Journal of Clinical Infectious Diseases, 2022, 15(4): 253-263.
|
| [9] |
LI M M, ZHANG W J, LIU J, et al. Dynamic changes in the immunological characteristics of T lymphocytes in surviving patients with severe fever with thrombocytopenia syndrome (SFTS)[J]. Int J Infect Dis, 2018, 70: 72-80.
|
| [10] |
SONG P X, ZHENG N, LIU Y, et al. Deficient humoral responses and disrupted B-cell immunity are associated with fatal SFTSV infection[J]. Nat Commun, 2018, 9(1): 3328.
|
| [11] |
KIM N, KIM K H, LEE S J, et al. Bone marrow findings in severe fever with thrombocytopenia syndrome: prominent haemophagocytosis and its implication in haemophagocytic lymphohistiocytosis[J]. J Clin Pathol, 2016, 69(6): 537-541.
|
| [12] |
周鑫, 朱建勇, 曾宪聪. 新型布尼亚病毒感染继发嗜血细胞综合征1例报道[J]. 中国临床研究, 2021, 34(4): 531-533.
|
|
ZHOU X, ZHU J Y, ZENG X C. A case report of haemophilic syndrome secondary to novel bunyavirus infection[J]. Chinese Journal of Clinical Research, 2021, 34(4): 531-533.
|
| [13] |
YOO J R, HEO S T, SONG S W, et al. Severe fever with thrombocytopenia syndrome virus in ticks and SFTS incidence in humans, south Korea[J]. Emerg Infect Dis, 2020, 26(9): 2292-2294.
|
| [14] |
LIANG B Y, XU L, LI M Y, et al. The association between elevated myocardial injury-related biomarker (TnI) and increased mortality in patients with severe fever with thrombocytopenia syndrome[J]. Crit Care Med, 2024, 52(10): 1509-1519.
|
| [15] |
FURUTA Y, GOWEN B B, TAKAHASHI K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor[J]. Antiviral Res, 2013, 100(2): 446-454.
|
| [16] |
SHIRAKI K, DAIKOKU T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections[J]. Pharmacol Ther, 2020, 209: 107512.
|
| [17] |
TANI H, FUKUMA A, FUKUSHI S, et al. Efficacy of T-705 (favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus[J]. mSphere, 2016, 1(1): e00061-15.
|
| [18] |
TAKAYAMA-ITO M, SAIJO M. Antiviral drugs against severe fever with thrombocytopenia syndrome virus infection[J]. Front Microbiol, 2020, 11: 150.
|
| [19] |
TANI H, KOMENO T, FUKUMA A, et al. Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: dose-efficacy studies upon oral administration[J]. PLoS One, 2018, 13(10): e0206416.
|
| [20] |
LI H, JIANG X M, CUI N, et al. Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome[J]. Signal Transduct Target Ther, 2021, 6(1): 145.
|
| [21] |
YUAN Y, LU Q B, YAO W S, et al. Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome[J]. EBioMedicine, 2021, 72: 103591.
|
| [22] |
SONG R, CHEN Z H, LI W. Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)[J]. Infection, 2020, 48(2): 295-298.
|
| [23] |
金灵薇. 法维拉韦治疗重症发热伴血小板减少综合征病例报道1例[J]. 世界最新医学信息文摘, 2021, 21(51): 301-302.
|
|
JIN L W. A case report of severe fever with thrombocytopenia syndrome treated with favipiravir[J]. World Latest Medical Information Abstracts, 2021, 21(51): 301-302.
|
| [24] |
刘亚萍, 臧玮. 法维拉韦治疗发热伴血小板减少综合征1例[J]. 中国新药与临床杂志, 2022, 41(11): 697-699.
|
|
LIU Y P, ZANG W. Favipiravir in treatment of severe fever with thrombocytopenia syndrome: a case report[J]. Chinese Journal of New Drugs and Clinical Remedies, 2022, 41(11): 697-699.
|
| [25] |
ZHANG Y, MIAO W, XU Y H, et al. Severe fever with thrombocytopenia syndrome in Hefei: clinical features, risk factors, and ribavirin therapeutic efficacy[J]. J Med Virol, 2021, 93(6): 3516-3523.
|
| [26] |
SHIMOJIMA M, FUKUSHI S, TANI H, et al. Effects of ribavirin on severe fever with thrombocytopenia syndrome virus in vitro[J]. Jpn J Infect Dis, 2014, 67(6): 423-427.
|
| [27] |
YAMAUCHI N, HONGO T, KAWAKAMI M, et al. Successful recovery from severe fever with thrombocytopenia syndrome and hemophagocytic lymphohistiocytosis with standard treatment and a calcium channel blocker of nicardipine hydrochloride[J]. Intern Med, 2023, 62(9): 1365-1369.
|
| [28] |
BANG M S, KIM C M, KIM D M, et al. Effective drugs against severe fever with thrombocytopenia syndrome virus in an in vitro model[J]. Front Med (Lausanne), 2022, 9: 839215.
|
| [29] |
ZHOU D, HUANG X B, ZHU L X, et al. Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China[J]. Blood, 2025, 146(3): 318-327.
|